PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/811,793

Filing Date Mar. 29, 2004

First Named Inventor Plachetka

Art Unit 1616

Examiner Name Choi, Frank

Attorney Docket Number

				DOCUMENTS	Desce Columns Lines Mines
xaminer nitials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
4	 	Number-Kind Code ² (7 known) US- 5,288,507	02-22-1994	Sims	cols. 1 and 4
\$	├	US- 6,106,862	08-22-2000	Chen	col. 3
\$	 	US- 5,415,870	05-16-1995	Gergely	col. 4
<u> </u>	<u> </u>	US-			
		US-			
		US-			
		UŞ.			
		US-			
		US-			
	↓	US-			
		US-			
	-	US-			
	-	US·			
		US-			
	+-	US-			
	1	US-			
	+	US-	·		
	- -	US-			

		FOREIC	ON PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T⁰
		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	02-11-1998	Sojvaku	page 3, line 40	
SZ		EP 0 823 255 A1	02-11-1990	Gelyako	Page 01	Ħ
						╂┯
	1					╄━┥
						-
						لسل

			Date	CII	1711DAC
Examiner	The Ober	•	Considered	X/	II WALLE
Signature	MM UND			01	17 07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For USPTO Patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by lapanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by lapanese patent document symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible is the language that the l

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, user including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief information Officer-U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND-FEES OR-COMPLETED FORMS TO THIS ABORESS.—SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Ĺ

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitute for form 1449/PTO	Application Number	10/811,793
INFORMATION DISCLOSURE	Filing Date	March 29, 2004
STATEMENT BY APPLICANT	First Named Inventor	Plachetka
	Art Unit	1616
(Use as many sheets as necessary)	Examiner Name	Choi, Frank 1
Sheet 2 of 2	Attorney Docket Number	

Examiner	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), volume-issue the item (book, magazine, journal, send, symposium, catalog, etc.), date, page(s), date	T ²
Z	110	the item (book, magazine, journal, senal, symposium, catalog, texture, number(s), publisher, city and/or country where published. MOORE, Drug treatment of migraine: Part I. Acute therapy and drug-rebound headache, Am Fam Physician, 1997, 2039-48,56(8), American Academy of Family Physicians, Kansas City, MO	
<u> </u>			
	-		
	-		
	-		
	_		-

		Date	Q111/mag
Examiner	$\nabla I \cap \mathcal{O}_{-}$	Considered	1 4/4/605
Signature	Mich Chan		itation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark hero if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent and Information Officer to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. U.S. Patent Information Officer the Information Officer the Information Officer the Information Officer Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

				Atty. Docket No.: 7569/8	30993	Appl No.: 1	0/811,793	
CISTADI	Æ FEF	RENCES CITED	BY APPLICANT	Applicant(s) Plache	tka, et al.			
AUG 05	2014 0 3	e several sheets if nece	ssary)	Filing Date: March 29, 2	004	Group: 🖘	e assigned	
133	- S		U.S. PAT	ENT DOCUMENTS				
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Da	ite priate
	AA I							
	ΑВΙ							
	AC 1							
	AD I						<u> </u>	
	AE 1			ļ		<u> </u>		
	AF 1						<u> </u>	
	AG I						<u> </u>	
			FOREIGN F	ATENT DOCUMENTS			Т	
		Document	Date	Country	Class	Subclass	Translat Yes	on No
		Number						
	AH I							
	Al 1							
	AJ I							
	AK 1	<u> </u>	OTTUER RRIOR ART (In	eluding Author Title Date Perlinet	nt Pages, Etc.)			
47	AL I			-		(400		
	AM 1							
	AN I							
	AOI							
	API			·				
	AQ 1							
	AR I		Filing Date: March 29, 2004 U.S. PATENT DOCUMENTS Date Name Class Subclass Filing Date If Appropriate FOREIGN PATENT DOCUMENTS Date Country Class Subclass Translation Yes No OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Release indicating Non-Approval of MT 100 Product of Pozen. (2004)					
	AS 1							
Examiner		Ih doi		Date Considered	8/4/	7005		

						· · · · · · · · · · · · · · · · · · ·		
	,			Atty. Docket No.: 7569/	80993	Appl No.: I	0/811,793	
LIST O	F REFE	RENCES CITED	BY APPLICANT	Applicant(s) Plache	tka, et al.			
1	/	se several shows if neces	sai y	Filing Date: March 29, 2	2004	Group: te-	oc assigned	I
	P. C. S.		. U.S. PA	TENT DOCUMENTS				
	- \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	40FM					Filing D	
Examiner Initial		Number	Date	Name	Class	Subclass	If Appro	priate
SZ	AA I	4,664,915	May 12, 1987	Simonian	424	128	Feb. 21,	1986
	AB							
	AC					<u> </u>		
	AD					ļ		
	AE							
	AF					<u> </u>		
	AG					<u> </u>		
			FOREIGN	PATENT DOCUMENTS				
							Abstr./T	rans.
		Document Number	Date	Country	Class	Subclass	Yes	No
\$c	AH I	CA 1,165,242	Apr. 10, 1984	Canada	A61K	31/605		ļ
まし	AI I	JP 58-8020	Jan. 18, 1983	Japan	A61K	47/00	x	
	AJ							ļ
	AK							
	1	. (OTHER PRIOR ART (II	ncluding Author, Title, Date, Pertinen	t Pages, Etc.)			
PL	AL I			pated Aspirin Preparation," A		5:45-50 (1976)		
	AM 1	Internet Adverti	sement for Migraleve.	(1998)				
	AN I	Material Safety	Data Sheet for Paraceta	mol D.C. (P.G.S.) (200	1)			
	AO 1	Abstract for Pow	wder Technology 33:107	-111 (1982), Krycer, et al., "	The Role of Intra-	Granular Porc	osity in Pov	vder
	AP I	Abstract for Dri	ug. Dev. Ind. Pharm. 26(chnique to Conventional	8):885-889 (2000), Railkar, e Methods."	et al., "Evaluation	and Comparis	son of a Mo	oist
	AQ I	Abstract for Dr	ug Dev Ind Pharm. 270	(4):337-343 (2001), Railkar, 6 Dosage Forms of Acetamino	et al., "Use of a M phen."	loist Granulati	on Techniq	lue
東	AR I		58-8020 reference All			<u> </u>		
	AS							
Examiner	. 7.	- N. A. (/		Date Considered	814/2	2005		
-		HUM (UNON)	in the state of th					

					Atty. Docket No.: 7569/	80993	Appl No.: 1	0/811,793	
LIS	- PF	REFER	ENCES CITED	BY APPLICANT	Applicant(s) Plache	etka, et al.			
M	ΑΥ 1	3 2004	in the same of the		Filing Date: March 29, 2	2004	Group: £0.1	e assigned 616	
12			\$	U.S. PAT	ENT DOCUMENTS				
Examine Initial	e In	ADEWAR	Document Number	Date	Name	Class	Subclass	Filing Da	
R		AA I	2,099,402	Nov. 16, 1937	Keller	167	82	Jan. 17, 1	934
<u> </u>	1	AB I	4,024,279	May 17, 1977	Zor, et al.	424	319	Jul. 24, 1	975
-	\dashv	AC I	4.235,971	Nov. 25, 1980	Howard, et al.	435	293	Jun. 9, 19	978
}	十	AD I	4,380,540	Apr. 19, 1983	Poyser, et al.	424	233	Jan. 18,	1982
	十	AE I	4,999,226	Mar. 12, 1991	Schock, et al.	424	472	Apr. 27,	1989
	\dashv			Aug. 6, 1991	Jones, et al.	514	222.8	Dec. 15,	1989_
7	\dashv	AF I	5,037,823	Oct. 8, 1991	Barry, et al.	424	482	Oct. 20,	1988
0,0		AG I	5,055,306		PATENT DOCUMENTS		•		
				FOREIGN	TIENT BOCOMBINE			Translati	ion
			Document Number	Date	Country	Class	Subclass	Yes	No
81	7	AH I	WO 95/22947	31 August 1995	WIPO	A 61P	5/04		
		All	EP 0 774 253	21 May 1997	ЕРО	A61K	31/165	<u>x</u>	
		AJI	BE 881 967	16 June 1980	Belgium	e 07 D		x	
A	$ egthinspace{-1pt}$	AK I	CA 2,020,018	27 June 1990	Canada	AGIK	31/52		
- V-		711(1)		OTHER PRIOR ART (In	cluding Author, Title, Date, Pertine	ent Pages, Etc.)			
57	,	AL I			1253 (1997).				
-		AMI	Translation for	AJ1 above.					
70	7	AN I	STN/CAS onlin		No. 1999161935 (Mandell, C	Cleveland Clinic Jo	urnal of Medic	cine 66:285	-292
X	·	AO 1	Albibi, et al., M	letoclopramide: Pharmac	cology and Clinical Applicat	tion, "Ann. Int. Med	d. 98:86-95 (1	983).	
T		AP I	Cephalalgia 9:2	29-32 (1989).	of Naproxen vs. Placebo in				
\$	Z	AQ I	(1989).		ons to Metoclopramide and				
J	Z	AR 1	(1994).		eview with Newer Options a				
\$	2	ASI	Becker, et al., ' Kinetic Study a Language Abs	and Consequences for M	ts of a Combination of Meto igraine Patients," <i>Arzneimitt</i>	oclopramide and Pa telforschung 42:552	aracetamol. R 2-555 (1992) (esults of a l including E	-luman English
Exam	niner		Phholoi		Date Considered	8/4/2	005		

				Atty. Docket No.: 7569/80	993	Appl No.: 1	0/811,793	
LIST C	F REFER	ENCES CITED	BY APPLICANT	Applicant(s) Plachetk	a, et al.			
	(Usa	e several sheets if nece	ssary)	Filing Date: March 29, 200)4	Group: اِمِا	6/6 c assigned	
·			U.S. PAT	ENT DOCUMENTS				
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date	
3	AA 2	5,155,105	Oct. 13, 1992	Jones, et al.	514	223.5	Jun. 19, 19	91
	AB 2	5,437,874	Aug. 1, 1995	Bru, et al.	424	466	Jan. 4, 199	4
	AC 2	5,573,776	Nov. 12, 1996	Harrison, et al.	424	435	Sep. 8, 199	94
	AD 2	5,681,583	Oct. 28, 1997	Conte, et al.	424	472	Apr. 25, 19	95
	AE 2	5,885,616	Mar. 23, 1999	Hsiao, et al.	424	472	Aug. 18, 1	997
\$C	AF 2	6,077,539	Jun. 20, 2000	Plachetka, et al.	424	474	Nov. 10, 1	997
_ 	AG					ļ ·		
		J	FOREIGN I	PATENT DOCUMENTS			·	
		Document	Date	Country	Class	Subclass	Translation	
	ļ	Number ⁻					Yes	No
	AH							
	Al		ļ				 	
	AJ					 		
	AK			<u> </u>			<u>l </u>	
		·		cluding Author, Title, Date, Pertinent P				
34	AL 2	35:264-269 (1	995)	aneous Sumatriptan with Usua				
	AM 2	Capobianco, et 71:1055-1066		e Diagnosis and Pharmacologi	c Treatment of	Migraine," <i>Ma</i>	nyo Clin. Proc	· ——
	AN 2	Chabriat, et al. Multicentre De	, "Combined Oral Lysing ouble-Blind Placebo-Con	e Acetylsalicylate and Metoclo strolled Study," Cephalalgia 14	pramide in the 2:297-300 (1994	Acute Treatme	ent of Migrain	ne: A
	AO 2	Chabriat, et al. Headache Qua	, "Combined Aspirin and arterly 8:118-121 (1997).	1 Metoclopramide in the Acute	Treatment of N	Aigraine Attac	ks: A Review	·,"
	AP 2		l., "Paracetamol and Met	oclopramide in Fixed Combin	ation," Med. Mo	ontasschr. Pha	rm. 19:110 (1	996)
	AQ 2			the Managed Care Formulary,	" Drug Benefit	Trends 8:28-3	0, 33-34, 41	
- -	AR 2	Consumer Ass	soc., "Metoclopramide/A	nalgesic Combinations for Mig	graine," <i>Drug a</i>	nd Therapeutic	es Bulletin 18:	95-
1	AS 2	96 (1980). Dechant, et al.	, "Sumatriptan: A Revie	w of Its Pharmacodynamic and graine and Cluster Headache,"	Pharmacokine	tic Properties,	and Therapeu	ıtic
Examiner	<u> </u>	Efficacy in the	Acute Freatment of Mil	Date Considered	G16 / / 5	005		

				Atty. Docket No.: 7569/80993	i	Appl No.: 1	0/811,793	
LISTO	F REFER	ENCES CITED several sheets if neces	BY APPLICANT	Applicant(s) Plachetka, e	t al.			
•	ezo)	severu meen y mee		Filing Date: March 29, 2004		Group: -to-l	e assigned	
			U.S. PATI	ENT DOCUMENTS				
Examiner Initial		Document Number	Date	Name .	Class	Subclass	Filing Da	
	AA		·					
	AB				ļ. <u> </u>			
	AC				ļ	ļ		
	AD				<u> </u>			
	AE				<u> </u>			
	AF							
	AG					<u> </u>	<u> </u>	
			FOREIGN P	ATENT DOCUMENTS			т	
		Document	Date	Country	Class	Subclass	Translat Yes	ion No
	-	Number						
	AH							
	AI							
	AJ							
	AK	<u></u>	OTHER PRIOR ART (luding Author, Title, Date, Pertinent Page:	Fic.)	<u></u>	<u> </u>	L
1	AL 3	Diamond, et al.	. "Do Non-Steroidal Ant	i-Inflammatory Agents Have a R		eatment of Mi	graine .	
1	AM 3		Drugs 37:755-760 (1989). or Steps in Managing Mig	graine," Postgraduage Medicine 8	5:121-124, 1	127-128, 131,	132-134 (1	989).
	AN 3	Eldor, et al., "E	Ergotamine-Metoclopram	ide for Migraine: Is It Enough?,"	Cephalalgia	<i>32</i> :466 (1992	2).	
	AO 3	Ellis, et al., "T	he Efficacy of Metoclopm	amide in the Treatment of Migrai	ne Headach	e," Ann. Emerg	g. Med. 22:	191-
	AP 3		Naproxen Formulations,"	Scand. J. Gastroenterol. 24:44-4	7 (1989).			
	AQ3	Ganzini, et al.,	"The Prevalence of Meto sorders," Arch. Intern. Me	oclopramide-Induced Tardive Dy d. 153:1469-1475 (1993).	skinesia and	Acute Extrap	yramidal	
	AR 3	Greiff, et al., "		nteractions with Gastrointesinal M	lotility Mod	ifying Agents,	" Clin.	
\$	AS 3	Gupta, et al., "		e on Gastric Ulceration and Secre	etion in Albi	no Rats," Arch	Int.	
Examiner		Theho		Date Considered	814	1 2005		

				Ally. Docker No	p.: 7569/80 9 93		Appl No.: 10		
LIST O	F REFER	ENCES CITED	BY APPLICANT	Applicant(s)	Plachetka, et	al.			
	(Use	several sheets if neces:	sary)	Filing Date: M	arch 29, 2004		Group: to be assigned		
			U.S. PAT	TENT DOCUMEN	TS				
xaminer nitial		Document Number			·	Class	Subclass	Filing Date If Appropriate	
	AA								
	AB						 		
	AC						 		
	AD								
	AE						 		
	AF			-			 		
	AG		<u> </u>				<u> </u>		
	. ,		FOREIGN	PATENT DOCUM	MENTS	T	T	Transla	tion.
	Document Number		Country		Class	Subclass	Yes	No	
	AH		·						
	Al							ļ	-
	AJ						 		
	AK					_L		<u>.l</u>	1
			OTHER PRIOR ART (
Th	AL4	25:451-494 (19	al., "Metoclopramide: A 983).						
	AM 4	Comparison w Abstract).	al., "Treatment of Migra ith Individual Drugs and	Placebo, Med. K			ne Tartrate and uding English	l Paracetan Language	nol in
	AN 4	Hughes, "Mete	oclopramide in Migraine	Treatment," Med.	J. Australia 2:51	80 (1977).			
	AO 4	Treatment of I	"Repeated Doses of Co Migraine," Headache 37	:434-434 (1997).				the Acute	
	AP 4		, "Naproxen Sodium in						
	AQ 4	Organization,	Kaa, et al., "Emergency Department Resource Use by Patients with Migraine and Asthma in a Health Maintenance Organization," Ann. Pharmacotherapy 29:251-256 (1995).						
	AR 4	Kandler, et al. (1993).	., "Analgesic Action of l	Metoclopramide in	Prosthetic Hip S				37:49-53
R	AS 4		"Effect of Metoclopram d Mouth-Cecum Transit	ide, Bethanechol, a Time," <i>Pharmaco</i>	nd Loperamide therapy 9:226-2	on Gastric R 31 (1989).	tesidence Tim	e, Gastric	
Examin	ner	Jah Ch	er.	Date Con			1005		

				Atty. Docket No.: 7569/8	0993	Appl No.: 1	0/811,793			
LIST O	F REFER	ENCES CITED	BY APPLICANT	Applicant(s) Plachet	ka, et al.					
	(Use	several sheets if neces	sary)	Filing Date: March 29, 20	Group: to be assigned>					
		. "	U.S. PAT	ENT DOCUMENTS		, -				
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Da If Appro			
	AA						<u> </u>			
	AB					 				
	AC					 				
	AD			 						
	AE					-				
	AF			<u> </u>		 				
	AG					<u> </u>	<u> </u>			
	1		FOREIGN F	PATENT DOCUMENTS		T	Γ			
		Document Number	Date	Country	Class	Subclass	Translat Yes	No		
	ÀH							ļi		
	Al						<u> </u>	ļ		
	AJ					<u> </u>				
	AK						<u> </u>			
			OTHER PRIOR ART (In	cluding Author, Title, Date, Pertinent	Pages, Etc.)			<u> </u>		
The	AL 5			mulary for the Treatment of		lache 35:225-2	227 (1995).			
	AM 5	Kumar, "Rece 9:339-348 (19	Kumar, "Recent Advances in the Acute Management of Migraine and Cluster Headaches," J. Gen. Intern. Med. 9:339-348 (1994).							
	AN 5	Manniche, et a ('Migravess'),	Manniche, et al., "The Pharmacokinetics of the Individual Constituents of an Aspirin-Metoclopramide Combination ('Migravess')," Curr. Med. Res. Opin. 9:153-156 (1984).							
	AO 5			ists and Other Agents in Acu	te Migraine," Ad	vances in Head	dache 15:61	1-81		
	AP 5		atment of Intractable Hea	daches," Neurology 36:101 (1986).					
	AQ 5	Ottervanger, "	'Ketorolac for Severe Mi	graine," Med. Sci. Bul. 26:49	(1994).					
	AR 5	Peroutka, "Be	eyond Monotherapy: Rati	onal Polytherapy in Migraine	e," Headache 38:	18-22 (1998).				
1	AS 5	Peroutka, "Do	opamine and Migraine,"	Neurology 49:650-656 (1997)). 					
Examine		Ship Cha		Date Considered	8/4/7	1009				

LIST OF REFERENCES CITED BY APPLICANT				Atty. Docket No.: 7569/80993 Appl No.: 10/811,793						
				Applicant(s) Plachetka, et al.						
	(Use	several sheets if necess	sary)	Filing Date: March 29, 2004	Group: to be assigned					
			U.S. PAT	ENT DOCUMENTS			<u> </u>			
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate			
	AA									
	AB				- 	 				
	AC				- 					
	AD		·							
	ΑE					 	 			
	AF									
	AG					<u> </u>				
			FOREIGN	PATENT DOCUMENTS						
		Document	Date	Country	Class	Subclass	Translat Yes	ion No		
	 	Number								
	AH									
	AI									
	AJ		-							
	AK		DELOR ART (ncluding Author, Title, Date, Pertinent P	ages. Etc.)					
-		T		AIDs in the Treatment of the A		Attack," Ceph	alalgia 15:	14-20		
30	AL 6	(1995).								
	AM 6	33:191-194 (1	Pini, et al., "Disposition of Naproxen after Oral Administration During and Between Migraine Attacks," Headacht 33:191-194 (1993).							
	AN 6	Plosker, et al. Migraine and	Plosker, et al., "Sumatriptan: A Reappraisal of Its Pharmacology and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache," Drugs 47:622-651 (1994).							
	AO 6	Bradalier at a	Pradalier, et al., "Treatment Review: Non-Steroid Anti-Inflammatory Drugs in the Treatment and Long-Terr Prevention of Migraine Attacks," <i>Headache 28</i> :550-557 (1988).							
	AP 6	Pryse-Phillip	s, et al., "Guidelines for t	the Diagnosis and Management	of Migraine ir	Clinical Pract	ice," Can. I	Med.		
-	AQ 6	Ross-Lee, et	:1273-1287 (1997). al., "Single-Dose Pharm:	acokinetics of Metoclopramide,	" Eur. J. Clin.	Pharmacol. 20	:465-471 (1	1981).		
-	_			inetics in Migraine. The Effect						
1	AR 6	24:777-785 ((1983).							
14	AS 6	Saadah, et al Tartrate Witl	., "Abortive Migraine Th h Caffeine," <i>Headache 3.</i>	nerapy with Oral Naproxen Sodi 2:95-97 (1992).	uili i lus ivicto	c	- 9-			
Examin	ner	Dyn O	· **	Date Considered	8/	1/2008				

				Atty. Dock	et No.: 7569/80993		Appl No.: 10	/811,793 		
LIST OF	REFERE	NCES CITED E	3Y APPLICANT	Applicant(s) Plachetka, et al.						
	(Use s	everal sheets if necessi	ary)	Filing Date: March 29, 2004			Group: to be assigned			
			U.S. PAT	TENT DOCU	MENTS		, 7			
xaminer nitial		Document Number	Date	Name	·	Class	Subclass	Filing Dat If Approp		
	AA			<u> </u>						
	AB			<u> </u>						
	AC			ļ						
	AD									
	AE					 	 			
	AF					ļ	 			
	AG			<u> </u>				<u> </u>		
			FOREIGN	PATENT DO	OCUMENTS					
							Subclass	Translati	ion	
		Document Number	Date	Country		Class	Suociass	Yes	No	
	АН	·				 			-	
	Ai								├	
	AJ									
	AK					<u> </u>		<u> </u>	<u> </u>	
	<u> </u>		OTHER PRIOR ART	(Including Author	r, Title, Date, Pertinent Page	es, Eic.)				
*	AL 7	Scherl, et al., "	Comparison of Dihydro	pergotamine w	vith Metoclopramide \ 59 (1995).	Versus Mep	eridine with Pr	omethazine	in the	
-5/ -	AM 7	Schwarzberg,	"Application of Metocle	opramide Spe	cificity in Migraine A	ttacks Thea	py," Headache	<i>34</i> :439-441		
	AN 7	Scott, "Dihydr	oergotamine: A Review cology 15:289-296 (199	ew of Its Use in the Treatment of Migraine and Other Headaches," Clin. 1992). Naproxen Sodium and Its Relationship to Clinical Analgesic Effects," Br. J. Clin. Results of a Survey of Self-Reported Migraineurs," Headache 35:387-396 (1995).						
	AO 7	Sevelius, et al	., "Bioavailability of Na							
	AP 7	Silberstein, "N	259-263 (1980). Migraine Symptoms: Re							
-	AQ 7	Tfelt-Hansen	, et al., "The Effectivene, natriptan for Migraine,"	ess of Combir	s of Combined Oral Lysine Acetylsalicylate and Metoclopramide Compared					
	AR 7		, et al., "Kombinationer i Behandlingen af Migra	_		1etoclopran 158:6345-63	nid Sammenlig 349 (1996) (inc	net Med Ore	al lish	
1	AS 7		stracty i, et al., "Effervescent N Attacks: A Double-Bli	Metoclopramid	le and Aspirin (Migra	vess) Versu 1984).	s Effervescent	Aspirin or I	Placebo	
Examir	ner ·	JA C		i i	te Considered	8/4/	/200 S			

			Atty. Docket No.: 7569/80993 Appl No.: 10/811,793							
LIST O	F REFER	ENCES CITED	BY APPLICANT	Ар	plicant(s) Plachetka, et	al.				
(Use several sheets if necessary)					ing Date: March 29, 2004	Group: 10-be assigned				
			U.S. PAT	ENT	DOCUMENTS					
Examiner Initial		Document Number Date			Name Class		Subclass	Filing Date If Appropriate		
	AA			<u> </u>		<u> </u>				
	AB			<u> </u>						
	AC			_			 			
	AD			\perp		ļ 				
	AE					ļ	-			
-	AF			1_		<u> </u>				
	AG					<u> </u>	<u> </u>	<u></u>		
			FOREIGN I	PATE	NT DOCUMENTS		τ	Γ		
		Document	Date	c	ountry	Class	Subclass	Translat Yes	no No	
	-	Number		1						
	AH			+					<u> </u>	
	Al			1						
	AJ			1					<u> </u>	
	AK	L	OTUED PRIOR ART (I		g Author, Title, Date, Pertinent Page	s, Etc.)				
TV	AL 8	Tfol: Honson "		f Met	oclopramide in the Treatmen		e Attacks," J.	Neurol.		
	AM 8	Thomson, "A S Treatment of M	Study to Compare Oral St ligraine," Eur. Neurol. 32	umatr 2:177-	iptan with Oral Aspirin Plus 184 (1992).					
	AN 8	Todd, et al., "N States," Drugs	Todd, et al., "Naproxen: A Reappraisal of Its Pharmacology, and Therapeutic Use in Rheumatic Diseases and Pain States," Drugs 40:91-137 (1990).							
	AO 8	Pharmac. 17:6	Tokola, et al., "Effects of Migraine Attack and Metoclopramide on the Absorption of Tolfenamic Acid, Br. J. Clin. Pharmac. 17:67-75 (1984).							
	AP 8	Attacks," Cepl	Tokola, et al., "Tolfenamic Acid, Metoclopramide, Caffeine and Their Combinations in the Treatment of Migraine Attacks," Cephalalgia 4:253-263 (1984).							
	AQ8	2:57-63 (1975)		he Absorption of Effervescer					
	AR 8	<i>36</i> :493-502 (1	996)		Headache Treatment Part 2:		aine Treatmen	t," Headac	he 	
8	AS 8	Welch, "Drug	Therapy of Migraine," A	Vew E	ngland J. Med. 329:1476-148	33 (1993).				
Examin	er	Truch	el_		Date Considered	3/4/	2005			

			Atty. Docket No.: 7:	569/80993	Appl No.: 10/811,793				
F REFE	RENCES CITED	BY APPLICANT	Applicant(s) Pl	achetka, et al.					
(Us	e several sheets if neces	sary) .	Filing Date: March	Filing Date: March 29, 2004			Group: to be assigned		
		U.S. PAT	ENT DOCUMENTS						
Document Number		Date	Name	Class	Subclass	Filing Date If Appropriate			
AA					 	<u> </u>			
AB	•								
AC					 				
AD					 				
AE			 						
AF									
AG			<u> </u>			<u></u> _			
		FOREIGN	PATENT DOCUMENT	rs		Ι			
	Document Number	Date	Country	Class	Subclass	Yes	No		
АН									
Al			·				<u> </u>		
AJ						ļ <u> </u>	ļ —		
AK		<u> </u>			J	<u>.</u>	<u> </u>		
						 			
AL9	Current Clinical	Experience," Cephalalg	ia 15:337-337 (1993).						
AM9	Wright, et al., "l	inearity of Metoclopran	nide Kinetics at Doses o	f 5-20 mg," <i>Br. J. Clin</i>	n. Pharmac. 26	:469-473 (1	988).		
AN							<u>. </u>		
АО									
AP									
AQ									
AR									
AS									
	The de a	e and the second of the second	Date Considered	8141	2005				
	AA AB AC AD AE AF AG AH AI AJ AK AL9 AM9 AN AO AP AQ AR	Document Number AA AB AC AD AE AF AG Document Number AH AI AI AJ AK AL 9 Wilkinson, et al. Current Clinical AM9 Wright, et al., "I AN AO AP AQ AR	Document Number AA AB AC AD AE AF AG Document Number Date FOREIGN FOREIGN AH AI AJ AK OTHER PRIOR ART (II AL 9 Wilkinson, et al., "Migraine and Cluster Current Clinical Experience," Cephalalg AM9 Wright, et al., "Linearity of Metoclopran AN AO AP AQ AR AS	FREFERENCES CITED BY APPLICANT (The several sheets if necessary) U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS Document Number AA AB AC AD AE AF AG Document Number Date FOREIGN PATENT DOCUMENT AH AI AI AJ AK OTHER PRIOR ART (Including Author, Title, Date, P AM9 Wright, et al., "Linearity of Metoclopramide Kinetics at Doses of AN AO AP AQ AR AS	Filing Date: March 29, 2004 U.S. PATENT DOCUMENTS Document Number Date Name Class AA AB CAD CLASS AF CAD COUNTY POREIGN PATENT DOCUMENTS Document Number Date Country Class AH AI CAD CLASS AH AI CAD CLASS AH AI CAD COUNTY CLASS OTHER PRIOR ART (Including Author, Title, Date, Perlinent Pages, Etc.) AL 9 Wilkinson, et al., "Migraine and Cluster Headache - Their Management with Sumatric Current Clinical Experience," Cephalalgia 15:337-357 (1995). AM9 Wright, et al., "Linearity of Metoclopramide Kinetics at Doses of 5-20 mg," Br. J. Clin AN AQ AR AS	FREFERENCES CITED BY APPLICANT (Use reveral them if mecessory) U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS Document Number AA AB AC AD AF AG FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS Class Subclass FOREIGN PATENT DOCUMENTS AB AI AI AI AI AI AI AI AV OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.) AN Wright, et al., "Migraine and Cluster Headache - Their Management with Sumatriptan: A Critical Current Clinical Experience," Cephalagia 15:337-337 (1995). AN AO AP AQ AR AR	FREFERENCES CITED BY APPLICANT (the several theast fracessory) U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS Document Number Date Name Class Subclass Filing Diffappro AA AB AC AD FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS Translat AF AG AG FOREIGN PATENT DOCUMENTS OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) AL 9 Wilkinson, et al., "Migraine and Cluster Headache - Their Management with Sumatriptan: A Critical Review of Current Clinical Experience," Cephalalgia 15:337-357 (1995). AM9 Wright, et al., "Linearity of Metoclopramide Kinetics at Doses of 5-20 mg," Br. J. Clin. Pharmac. 26:469-473 (1) AR AR AR AR AS		